Rational Computational Study for New Kinase Inhibitors
Journal of Drug Design and Medicinal Chemistry
Volume 5, Issue 3, September 2019, Pages: 40-46
Received: Jun. 25, 2019; Accepted: Aug. 6, 2019; Published: Sep. 2, 2019
Views 64      Downloads 21
Authors
Joao Eustaquio Antunes, Department of Pharmacy, Federal University of Juiz de Fora, Governador Valadares, Brazil
Michelle Bueno de Moura Pereira, Department of Life Basic Sciences, Federal University of Juiz de Fora, Governador Valadares, Brazil
Article Tools
Follow on us
Abstract
The development of new drugs can present several problems, it is a important obstacle the ability to adapt a molecule that is a potent pharmacological inhibitor and that is also possible to execute its synthesis. Quinazolines are known to be capable of inhibiting kinases. Thus, a detailed study was carried out to propose new quinazolines with already known synthetic routes, and that were promising for the ability to inhibit kinases. A drug candidate molecule shall be proposed to have a good absorption, an extensive distribution so it’s capable of reaching the desired therapeutic targets. Lipinski's Rule of 5 in computational studies has been applied to select more promising molecules. In this study, the molecules proposed for the synthesis were systematically designed in appropriate computational programs to test several substituents of the quinazoline nucleus on the capacity of these molecules to be considered inhibitors of kinases. Six molecules were selected with the best results to inhibit kinases. In the study to evaluate the variation of substituents, the result obtained for the 8-position of the quinazoline ring and with the -Cl substituent at that ring position presented 60% of the 10 best molecules capable of inhibiting kinases. The molecular docking study confirmed that the two most promising molecules to inhibit kinase also obtained the best results to inhibit AKT kinase. Therefore, through this study it was possible to select six more promising molecules to be synthesized and available in large screening tests for several therapeutic targets known as High-Throughput Screening.
Keywords
Kinase Inhibitor, Quinazoline, Molecular Docking
To cite this article
Joao Eustaquio Antunes, Michelle Bueno de Moura Pereira, Rational Computational Study for New Kinase Inhibitors, Journal of Drug Design and Medicinal Chemistry. Special Issue: Drug Discovery of New Kinases Inhibitors. Vol. 5, No. 3, 2019, pp. 40-46. doi: 10.11648/j.jddmc.20190503.12
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
David E. Golan, Armen H. Tashjian, Jr., Ehrin J. Armstrong, April W. Aemstrong, Principle of Pharmacology, 2ª ed. 2008, Willians & Wilkins. 3-7.
[2]
Barreiro, E. J. As Bases Moleculares da Ação dos Fármacos, Fraga, C. A. M 2ª ed.; Porto Alegre, 2008, P.41.
[3]
http://www.molinspiration.com access in 25/04/2019.
[4]
Fernandes, G. S.; Pereira, M. B. M.; Freitas, M. P.; Antunes, J. E. Open Journal of Medicinal Chemistry, 2015, 5, 106-115.
[5]
Thomas, G. In Computer Aided Drug. Fund. Med. Chem. 2003, 98-109.
[6]
Levitzki, A.; Mishani E. Annual Review Biochemistry 2006, 75, 93.
[7]
Connolly, D. J.; Cusack, D.; O´Sullivan, T. P.; Guiry, P. J. Tetrahedron 2005, 61, 10153.
[8]
Tobe, M.; Isobe, Y.; Tomizawa, H.; Nagasaki, T.; Takahashi, H.; Fukazawa, T.; Hayashi, H.. Bioorg. & Med. Chem. 2003, 11: 383–391.
[9]
ACD ChemSketch versão 8.17, 2005. www.acdlabs.com/products/draw_nom/draw.
[10]
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug Deliv. Rev. 1997, 23:3-25.
[11]
https://www.rcsb.org/ access in 02/05/2019.
[12]
Thomsen, R.; Christensen, M. H.; MolDock: A new technique for high-accuracy molecular docking. Journ. Med. Chem. 2006, 49: 3315-21.
[13]
Lipinski, C. A. Drug-Like Proprerties and the Causes of Poor Solubility and Poor Permeability, J. Pharmacol. Toxicol. Methods. 2000, 44: 235-249.
[14]
Fernandes, G. S.; Pereira, M. B. M.; dos Santos, G. R. R. M.; Antunes, J. E. New method for predict biological activity of kinases inhibitors, SCIREA Journal of Chemistry, V2, Issue 2, 2017.
[15]
Golan, D. E.; Tashjian, A. H.; Jr.; Armstrong, E. J. April W. Armstrong, A. W. Principle of Pharmacology, 2a ed. 2009, Willians & Wilkins,. Cap. 1.
[16]
Wu P, Nielsen TE, Clausen MH. Drug Discov Today. 2015 Jul; 36 (7):422-39.
[17]
Al‐Damluji, S.; Kopin, I. J. Br. Journal of Pharmacology 1998, 124, 693.
[18]
Murer B. Targeted therapy in non-small cell lung cancer: a commentary. Arch Path Lab Med 2008; (132):1573-1575.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186